hydromorphone hydrochloride + flurbiprofen axetil

Hydromorphone hydrochloride + flurbiprofen axetil is a multimodal analgesic combination therapy utilized for the management of moderate-to-severe pain, particularly in the perioperative setting. Hydromorphone hydrochloride is a potent opioid analgesic that acts as a selective mu-opioid receptor agonist, providing central analgesia by modulating pain perception in the central nervous system. Flurbiprofen axetil is an injectable prodrug of flurbiprofen, a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of peripheral prostaglandins involved in inflammation and pain signaling. This combination is often administered via patient-controlled intravenous analgesia (PCIA) to achieve synergistic pain relief, which can lead to reduced opioid consumption and a lower incidence of opioid-related adverse effects. It has been specifically studied for post-procedural pain management in patients undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma.

Other names

hydromorphone + flurbiprofen axetilhydrochloride hydromorphone + flurbiprofen axetilhydrochloride hydromorphone + flurbiprofen ester